Who buys zomedica (Zom) stock?
Apr 13, 2022 · ZOM Zomedica Pharmaceuticals Corp — Stock Price and Discussion | Stocktwits. Zomedica Pharmaceuticals Corp NYSEArca Updated Apr 14, 2022 8:00 PM. ZOM 0.31 0.01 (1.80%) 130,660. Key Data. 52wk Low 0.27.
What does Zom stand for?
Mar 25, 2022 · ZOM | Complete Zomedica Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Is Zom stock up 100% again?
Apr 15, 2022 · Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs.
Where can I buy shares of Zom?
Apr 14, 2022 · View Zomedica Corp ZOM investment & stock information. Get the latest Zomedica Corp ZOM detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.
Is ZOM stock expected to go up?
The 1 analysts offering 12-month price forecasts for Zomedica Corp have a median target of 1.20, with a high estimate of 1.20 and a low estimate of 1.20. The median estimate represents a +292.16% increase from the last price of 0.31.
Is ZOM good to invest in?
ZOM stock is a risky bet in the pet diagnostics field, but it's affordable and could provide powerful gains in the long-term. Or its downward spiral could continue; that's a possibility which prospective investors should always consider.Jan 7, 2022
Will ZOM stock recover?
There is potential for a short term uptick in the Zom stock price, especially as the active weekly candle is mildly bullish. The relative strength index is relatively oversold and has been for quite some time. A mild divergence also supports the notion of a slight recovery in the Zom stock price in the near term.Feb 4, 2022
Why is ZOM dropping?
CEO Robert Cohen said the move was precipitated by "changes at our current distributor that we believe have impacted its ability to market our products effectively." Those words likely startled investors, many of whom decided to sell their shares. Zomedica's stock price dropped sharply on Thursday.Apr 15, 2021
Is ZOM undervalued?
InvestorPlace's Mark Hake estimates Zomedica (NYSEAMERICAN:ZOM) is worth between $1.11 and $1.61 a share. That makes ZOM stock a buy at current prices.Jun 28, 2021
Is Acasti Pharma a good stock to buy?
Is ACASTI PHARMA Stock a good buy in 2022, according to Wall Street analysts? The consensus among 1 Wall Street analyst covering (NASDAQ: ACST) stock is to Buy ACST stock.
Is Zomedica a pump and dump?
Zomedica Pharmaceuticals (NYSEMKT:ZOM) stock is the latest pump-and-dump looking to take investors for a ride.Jan 21, 2021
About Zomedica
Zomedica (NYSEAMERICAN:ZOM) Frequently Asked Questions
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs.
What is Zomedica's goal?
Zomedica's stock was trading at $0.2078 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ZOM stock has increased by 63.8% and is now trading at $0.3403. View which stocks have been most impacted by COVID-19.
When will Zomedica start commercializing Truforma?
Specifically, the company works to develop and commercialize pharmaceuticals for pets like dogs and cats. In its pipeline, Truforma is one of its key focuses. This point-of-care platform works to detect certain thyroid and adrenal issues in dogs and cats. Importantly, Zomedica works with Qorvo Biotechnologies to develop ...
What is a ZM-017?
To start, Zomedica plans to start commercializing its Truforma platform sometime in March 2021. Ahead of that business update, many investors are trying to get in on the so-called ground floor of this pet care play.
What is Stock Sentiment?
The first is ZM-020, a point-of-care platform for urine and fecal testing. The second is ZM-017, a canine cancer liquid biopsy platform. Investors should also note that ZM-017 is in the validation stage, and focuses on liquid biopsies for hemangiosarcoma and osteosarcoma.
More About Zomedica Corp
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
What does Zomedica do?
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health.
When did Zomedica come on the NYSE?
What does Zomedica Pharmaceuticals do? Zomedica is a pet health company. Specifically, the company creates point-of-care solutions for dogs and cats. Recently, Zomedica trademarked a biosensor immunoassay platform called TRUFORMA™, which detects thyroid disease and adrenal disease in pets.
Is Zomedica going to delist?
Zomedica first came onto the NYSE American on July 1, 2020. Since then, the stock has faltered to as low as $0.06. For companies that aren't new to the exchange, the NYSE American maintains a minimum share price of $0.20. As a result, Zomedica faced the risk of getting delisted.
Does Zomedica have a reverse stock split?
Since Zomedica has been in that position in the past, it might face delisting again. If that happens, investors will be required to trade their securities on the OTC markets or something similar. Trading volumes are lower here, which can decrease value.
Is Zomedica going out of business?
To combat this, some companies perform a reverse stock split, which reduces the number of overall stocks available but increases the price per share. Zomedica tried to do this, but the company didn't receive shareholder approval. Despite the struggles, Zomedica is finally gaining some upward traction.
Is Zomedica still in clinical?
Zomedica isn't going out of business. On Jan. 1, Zomedica announced that Robert Cohen would be the new CEO. Cohen has been part of the company since the start of its biosensor research. Previously, he served as the interim CEO.
Is Zomedica delisted?
Zomedica's new product is promising. It's also still in-clinic, which means investing in the company early could potentially provide decent returns. However, Zomedica has a fairly low market capitalization and a low cost per share. In 2018, the company thrived on other exchanges, but it fell by 2019 (down 91.61 percent over a 12-month period).